Evidence map›Paper›PMID 25295618›Full record

ArticlePloS one2014

ICln: a new regulator of non-erythroid 4.1R localisation and function.

Claudia Bazzini, Lorena Benedetti, Davide Civello, Chiara Zanoni, Valeria Rossetti, Davide Marchesi, Maria Lisa Garavaglia, Markus Paulmichl, Maura Francolini, Giuliano Meyer and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Expression of Protein 4.1 Family in Breast Cancer: Database Mining for 4.1 Family Members in Malignancies.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Claudia BazziniDepartment of Biosciences, University of Milan, Milan, Italy.
Lorena BenedettiDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy; Fondazione Filarete for Biosciences and Innovation, Milan, Italy.
Davide CivelloDepartment of Biosciences, University of Milan, Milan, Italy.
Chiara ZanoniPharmaceutical Sciences Department (DISFARM), University of Milan, Milan, Italy.
Valeria RossettiDepartment of Biosciences, University of Milan, Milan, Italy.
Davide MarchesiFondazione Filarete for Biosciences and Innovation, Milan, Italy.
Maria Lisa GaravagliaDepartment of Biosciences, University of Milan, Milan, Italy.
Markus PaulmichlInstitute of Pharmacology and Toxicology, Paracelsus Medical University, Salzburg, Austria.
Maura FrancoliniDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy; Fondazione Filarete for Biosciences and Innovation, Milan, Italy.
Giuliano MeyerDepartment of Biosciences, University of Milan, Milan, Italy.
Simona RodighieroFondazione Filarete for Biosciences and Innovation, Milan, Italy.
University of Milan · ITFondazione Filarete · ITParacelsus Medical University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To optimise the efficiency of cell machinery, cells can use the same protein (often called a hub protein) to participate in different cell functions by simply changing its target molecules. There are large data sets describing protein-protein interactions ("interactome") but they frequently fail to consider the functional significance of the interactions themselves. We studied the interaction between two potential hub proteins, ICln and 4.1R (in the form of its two splicing variants 4.1R80 and 4.1R135), which are involved in such crucial cell functions as proliferation, RNA processing, cytoskeleton organisation and volume regulation. The sub-cellular localisation and role of native and chimeric 4.1R over-expressed proteins in human embryonic kidney (HEK) 293 cells were examined. ICln interacts with both 4.1R80 and 4.1R135 and its over-expression displaces 4.1R from the membrane regions, thus affecting 4.1R interaction with ß-actin. It was found that 4.1R80 and 4.1R135 are differently involved in regulating the swelling activated anion current (ICl,swell) upon hypotonic shock, a condition under which both isoforms are dislocated from the membrane region and thus contribute to ICl,swell current regulation. Both 4.1R isoforms are also differently involved in regulating cell morphology, and ICln counteracts their effects. The findings of this study confirm that 4.1R plays a role in cell volume regulation and cell morphology and indicate that ICln is a new negative regulator of 4.1R functions.

Indexed as

Cell LineCytoskeletal ProteinsCytoskeletonELAV-Like Protein 2ELAV ProteinsHEK293 CellsHumansMembrane ProteinsProtein BindingProtein IsoformsCytoskeletal ProteinsELAVL2 protein, humanELAV-Like Protein 2ELAV Proteinserythrocyte membrane band 4.1 proteinMembrane ProteinsProtein Isoforms

Identifiers

PMID25295618
PMCPMC4189953
OpenAlexW2031037227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.